Patent thickets not a problem, says US court in AbbVie case
The company’s controversial Humira IP strategy is not anticompetitive, says the Court of Appeals for the Seventh Circuit
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.